OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence
The settlement is among the largest in a series of settlements by drugmakers, wholesalers and pharmacies in recent years.
Pharmaceutical
Lilly acquiring cancer-drug firm Ajax Therapeutics in deal worth up to $2.3B
The acquisition is the latest in a series of recent deals that Indianapolis-based Eli Lilly and Co. has made to increase its cancer-treatment pipeline.
Complex process leads to a new drug’s identity
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal analysis and regulatory compliance.
FDA plans ultra-fast review of three psychedelic drugs following Trump directive
President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed research and loosen restrictions on psychedelics, a class of hallucinogenic drugs that remain illegal under federal law.
Insurers balk at Trump’s plan to cover obesity drugs in Medicare
Health insurers are raising questions about the Trump administration’s plan to cover obesity drugs in Medicare next year.
Judge postpones OxyContin-maker Purdue Pharma’s sentencing to let opioid victims attend in person
The judge had been expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the U.S. government.
Purdue Pharma to be sentenced in criminal opioids case, allowing settlement money to flow
The criminal sentence Tuesday will mark a major step toward the company finalizing a settlement of thousands of lawsuits it faces over the toll of opioids.
UPDATE: Eli Lilly acquiring Boston-based biotech in deal worth up to $7B
Lilly has been bringing in record revenue from its weight-loss medicines, but continues to diversify its pipeline candidates through acquisitions of biotech companies that are developing new genetic therapies for cancer and other disorders.
What is ‘Ozempic personality’ and why does it make life feel ‘meh’?
The new class of GLP-1 drugs are generally considered safe. Their metabolic effects have been scrutinized in studies, but their psychological impact is far less understood.
Telix Pharmaceuticals to collaborate with Regeneron on cancer therapies
Through the collaboration, Telix and Regeneron expect to develop and commercialize next-generation radiopharmaceutical therapies targeting cancer.
Trump unveils 100% tariff on some patented drugs on ‘Liberation Day’ anniversary
Trump wrote that he deemed such actions necessary “to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.”
FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity
The daily oral medication, which will be branded as Foundayo, is expected to begin shipping Monday.
Novo Nordisk to cut 400 jobs in Bloomington
The drugmaker called the move a “difficult decision” but did not provide a reason for the cuts.
Lilly to acquire UK-based pharmaceutical company in deal worth up to $7.8B
Centessa Pharmaceuticals is developing treatments to address daytime sleepiness and other neurological conditions.
Obesity drug trials complicated by placebo patients leaving early
The companies developing new weight-loss medicines have a problem: People who don’t lose weight quickly figure out they were assigned to take a placebo and are bailing out of their clinical trials.
Lilly’s experimental diabetes shot yields record weight loss in study
The late-stage results handily beat earlier trials of the company’s diabetes blockbuster Mounjaro, which racked up sales of $23 billion in 2025.
Lilly spending $1.8B to update Indianapolis manufacturing operations
The Lilly Technology Center investment includes expanding existing capabilities and the establishment of new production lines.
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers after an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform.
Chief technology officer spent whole career at Lilly
Tim Coleman has held positions within information technology at Lilly in research and development, sales and marketing, manufacturing, and human resources.
Generic Ozempic could cost less than $3 a month, study shows
Generic Ozempic is set to emerge in major markets from India and Brazil to China and Canada this year, reshaping the sector in those countries.